Zydus Life Shares Surge on Bioeq Partnership for US Biosimilar Market

• Zydus Lifesciences' shares gained after its subsidiary partnered with Swiss biopharmaceutical company Bioeq AG.
• The partnership is for licensing, supply, and commercialization of Bioeq’s NUFYMCO, a biosimilar of Lucentis, in the US market.
• Bioeq will handle development, manufacturing, and supply, while Zydus will commercialize NUFYMCO in the US.
• The USFDA approved the Biologics License Application (BLA) for NUFYMCO on December 18, 2025.
• Zydus also recently partnered with Myriad Genetics for cancer tests in India and its subsidiary Sentynl had FDA accept resubmission for CUTX-101.

Why It Matters: Zydus Life's strategic partnership with Bioeq for US biosimilar market boosts investor confidence.